Provectus Biopharmaceuticals Announces Acceptance of PV-10® Melanoma Abstract for Oral Presentation at Melanoma Bridge 2020
12. November 2020 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company's ongoing Phase 1b/2 study of autolytic cancer immunotherapy PV-10, an injectable...